EyePoint Pharmaceuticals announced the appointment of Fred Hassan to its Board of Directors. Previously, Mr. Hassan served as Chairman of the Board and CEO of Schering-Plough Corporation from 2003 to 2009. Additionally, the Company announced that Anthony P. Adamis, M.D. and David Guyer, M.D. have resigned from their positions as directors on the Company’s Board due to their transition to full-time roles at Merck & Co
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
- EyePoint initiated with a Buy at Jefferies
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint reports inducement grants under NASDAQ listing rule